Cue Biopharma (CUE) Depreciation & Amortization (CF) (2017 - 2025)
Cue Biopharma (CUE) posted Depreciation & Amortization (CF) of $678000.0 for Q4 2025, up 747.5% sequentially from $80000.0 in Q3 2025, and up 591.84% YoY from $98000.0 in Q4 2024.
Cue Biopharma (CUE) Depreciation & Amortization (CF) (2017 - 2025) Analysis & Trends
Cue Biopharma has reported Depreciation & Amortization (CF) for 9 years, with the latest figure at $678000.0 in Q4 2025.
- Quarterly Depreciation & Amortization (CF) rose 591.84% year-over-year to $678000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $958000.0 (up 141.31% YoY) and the FY2025 annual result came in at $958000.0, up 141.31% from the prior year.
- Depreciation & Amortization (CF) improved to $678000.0 in Q4 2025 per CUE's latest filing, from $80000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $678000.0 in Q4 2025 and troughed at $80000.0 in Q3 2025.
- A 5-year average of $204533.1 and a median of $156500.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) slumped 44.33% in 2023, then soared 591.84% in 2025.
- Over 5 years, Depreciation & Amortization (CF) stood at $309662.0 in 2021, then tumbled by 34.44% to $203000.0 in 2022, then plunged by 44.33% to $113000.0 in 2023, then decreased by 13.27% to $98000.0 in 2024, then jumped by 591.84% to $678000.0 in 2025.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $678000.0, $80000.0, and $99000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 678,000.00 |
| Dec 31, 2025 | 678,000.00 |
| Sep 30, 2025 | 80,000.00 |
| Sep 30, 2025 | 80,000.00 |
| Jun 30, 2025 | 99,000.00 |
| Jun 30, 2025 | 99,000.00 |
| Mar 31, 2025 | 101,000.00 |
| Mar 31, 2025 | 101,000.00 |
| Dec 31, 2024 | 98,000.00 |
| Dec 31, 2024 | 98,000.00 |
| Sep 30, 2024 | 101,000.00 |
| Sep 30, 2024 | 101,000.00 |
| Jun 30, 2024 | 99,000.00 |
| Jun 30, 2024 | 99,000.00 |
| Mar 31, 2024 | 99,000.00 |
| Mar 31, 2024 | 99,000.00 |
| Dec 31, 2023 | 113,000.00 |
| Dec 31, 2023 | 113,000.00 |
| Sep 30, 2023 | 130,000.00 |
| Sep 30, 2023 | 130,000.00 |